


(-)-Pinoresinol 4-O-glucoside

Cat. No.:	HY-N0946
CAS No.:	41607-20-9
Molecular Formula:	C ₂₆ H ₃₂ O ₁₁
Molecular Weight:	520.53
Target:	Glucosidase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	(-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC ₅₀ value of 48.13 μM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease ^{[1][2]} .														
IC₅₀ & Target	IC ₅₀ : 48.13 μM (α-Glucosidase) ^[1]														
In Vitro	<p>(-)-Pinoresinol 4-O-glucoside (0, 10, 30 μM; 24 h) increases cell migration during the differentiation of pre-osteoblasts in osteogenic supplement medium (OS) containing 50 μg/mL^[1].</p> <p>(-)-Pinoresinol 4-O-glucoside (10, 30 μM; 7 days) increases the early differentiation and increases mineralized nodule formation during differentiation of pre-Osteoblasts^[1].</p> <p>(-)-Pinoresinol 4-O-glucoside (10, 30 μM; 3 days) increases the expressio of BMP2, ALP, OCN mRNA levels in pre-osteoblasts^[1].</p> <p>(-)-Pinoresinol 4-O-glucoside (10, 30 μM; 3 days) increases protein level of BMP2, p-Smad1/5/8, RUNX2^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>RT-PCR^[1]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>pre-osteoblasts</td> </tr> <tr> <td>Concentration:</td> <td>10, 30 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>3 days</td> </tr> <tr> <td>Result:</td> <td>Upregulated the mRNA level of BMP2 and its target osteoblast genes, ALP and osteocalcin (OCN).</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>pre-osteoblasts</td> </tr> <tr> <td>Concentration:</td> <td>10, 30 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>3 days</td> </tr> </table>	Cell Line:	pre-osteoblasts	Concentration:	10, 30 μM	Incubation Time:	3 days	Result:	Upregulated the mRNA level of BMP2 and its target osteoblast genes, ALP and osteocalcin (OCN).	Cell Line:	pre-osteoblasts	Concentration:	10, 30 μM	Incubation Time:	3 days
Cell Line:	pre-osteoblasts														
Concentration:	10, 30 μM														
Incubation Time:	3 days														
Result:	Upregulated the mRNA level of BMP2 and its target osteoblast genes, ALP and osteocalcin (OCN).														
Cell Line:	pre-osteoblasts														
Concentration:	10, 30 μM														
Incubation Time:	3 days														

	<table border="1"> <tr> <td>Result:</td> <td>Enhanced protein level of BMP2, followed by the phosphorylation of Smad1/5/8 and the expression of RUNX2.</td> </tr> </table>	Result:	Enhanced protein level of BMP2, followed by the phosphorylation of Smad1/5/8 and the expression of RUNX2.						
Result:	Enhanced protein level of BMP2, followed by the phosphorylation of Smad1/5/8 and the expression of RUNX2.								
In Vivo	<p>(-)-Pinoresinol 4-O-glucoside (50 mg/kg; p.o.; twenty days) attenuates oxidative stress, hyperglycaemia and hepatic toxicity in mice^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>27-30 g, Male Swiss albino mice^[2]</td> </tr> <tr> <td>Dosage:</td> <td>50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>P.o.; twenty days</td> </tr> <tr> <td>Result:</td> <td>Exhibited a hepatoprotective activity in vivo as it lowered AST and ALT levels, caused a prominent decline in serum glucose level by 37.83% in streptozotocin-treated mice with promising elevation in insulin level of 25.37%.</td> </tr> </table>	Animal Model:	27-30 g, Male Swiss albino mice ^[2]	Dosage:	50 mg/kg	Administration:	P.o.; twenty days	Result:	Exhibited a hepatoprotective activity in vivo as it lowered AST and ALT levels, caused a prominent decline in serum glucose level by 37.83% in streptozotocin-treated mice with promising elevation in insulin level of 25.37%.
Animal Model:	27-30 g, Male Swiss albino mice ^[2]								
Dosage:	50 mg/kg								
Administration:	P.o.; twenty days								
Result:	Exhibited a hepatoprotective activity in vivo as it lowered AST and ALT levels, caused a prominent decline in serum glucose level by 37.83% in streptozotocin-treated mice with promising elevation in insulin level of 25.37%.								

REFERENCES

- [1]. Park KR, et al. Effects of PIN on Osteoblast Differentiation and Matrix Mineralization through Runt-Related Transcription Factor. *Int J Mol Sci.* 2020 Dec 16;21(24):9579.
- [2]. Youssef FS, et al. Pinoresinol-4-O-β-D-glucopyranoside: a lignan from prunes (*Prunus domestica*) attenuates oxidative stress, hyperglycaemia and hepatic toxicity in vitro and in vivo. *J Pharm Pharmacol.* 2020 Dec;72(12):1830-1839.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA